Medical News / From AAO 2021 - Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab was noninferior to aflibercept in the treatment of center-involving diabetic macular edema (DME) in visual acuity at 52 weeks. During an interview with HCPLive, Dilsher Dhoot, MD, California Retina Consultants, discussed his presentation on the outcomes of the KESTREL and KITE studies. In terms of fluid outcomes, data show that brolucizumab may have dried the retina better, compared to aflibercept, over the 52 week study period. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the ... read more
Access to US ophthalmology clinical trial sites may differ by region, according to new study findings ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more
Over the weekend, important data on avacincaptad pegol treatment in patients from the GATHER1 clinical trial ... read more